Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 437-453 , September 2008

Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation

  • Katayoun Rezvani, MBBS, PhD, MRCP, FRCPath (Clinical Senior Lecturer)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 0 208 383 2175; Fax: +44 0 20 8742 9335.

References 

  1. Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. British Journal of Haematology. 1957;3:241–252
  2. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New England Journal of Medicine. 1979;300:1068–1073
  3. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New England Journal of Medicine. 1981;304:1529–1533
  4. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  5. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood. 1993;82:2273–2277
  6. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310–2318
  7. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  8. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:2742–2747
  9. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94:1201–1208
  10. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  11. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–819
  12. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100:3825–3827
  13. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006;20:1661–1672
  14. Dazzi F, Fozza C. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Practice & Research. Clinical Haematology. 2007;20:311–327
  15. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nature Reviews. Cancer. 2004;4:371–380
  16. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–415
  17. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nature Medicine. 2004;10:987–992
  18. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine. 2002;8:575–581
  19. Reddy P, Maeda Y, Liu C, et al. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nature Medicine. 2005;11:1244–1249
  20. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87:3587–3592
  21. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198–2203
  22. Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450–2457
  23. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529–2534
  24. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99–107
  25. Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. Journal of Experimental Medicine. 1992;176:157–168
  26. Goulmy E. Human minor histocompatibility antigens. Current Opinion in Immunology. 1996;8:75–81
  27. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–389
  28. Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Annals of Internal Medicine. 1994;120:646–652
  29. Barrett AJ, Ringden O, Zhang MJ, et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000;95:3323–3327
  30. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine. 2000;6:1018–1023
  31. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892–2900
  32. Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood. 2007 Sep 15;110(6):1924–1932
  33. Rezvani K, Price D, Brenchley J, et al. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy. 2007;9:245–251
  34. Vavassori M, Maccario R, Moretta A, et al. Restricted TCR repertoire and long-term persistence of donor-derived antigen-experienced CD4+ T cells in allogeneic bone marrow transplantation recipients. Journal of Immunology. 1996;157:5739–5747
  35. Verfuerth S, Peggs K, Vyas P, et al. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood. 2000;95:3990–3995
  36. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunology Today. 1997;18:245–251
  37. Sebzda E, Mariathasan S, Ohteki T, et al. Selection of the T cell repertoire. Annual Review of Immunology. 1999;17:829–874
  38. Gannage M, Abel M, Michallet AS, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. Journal of Immunology. 2005;174:8210–8218
  39. Rezvani K, Brenchley JM, Price DA, et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clinical Cancer Research. 2005;11:8799–8807
  40. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100:2132–2137
  41. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity. 1999;11:183–190
  42. Clarke SR, Rudensky AY. Survival and homeostatic proliferation of naive peripheral CD4+ T cells in the absence of self peptide:MHC complexes. Journal of Immunology. 2000;165:2458–2464
  43. Cho BK, Rao VP, Ge Q, et al. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. Journal of Experimental Medicine. 2000;192:549–556
  44. Krupica T, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: a two-hit model. Clinical Immunology. 2006;120:121–128
  45. Tsutsumi Y, Tanaka J, Miura Y, et al. Molecular analysis of T-cell repertoire in patients with graft-versus-host disease after allogeneic stem cell transplantation. Leukemia & Lymphoma. 2004;45:481–488
  46. Jones SC, Friedman TM, Murphy GF, et al. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Biology of Blood and Marrow Transplantation. 2004;10:91–105
  47. Mohty M, Mohty AM, Blaise D, et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplantation. 2004;33:839–846
  48. Matsushita M, Yamazaki R, Ikeda H, et al. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. British Journal of Haematology. 2006;132:56–65
  49. Michalek J, Collins RH, Hill BJ, et al. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet. 2003;361:1183–1185
  50. Hellstrom KE, Hellstrom I, Kant JA, et al. Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. Journal of Experimental Medicine. 1978;148:799–804
  51. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. Journal of Experimental Medicine. 2005;202:907–912
  52. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. Journal of Clinical Investigation. 2002;110:185–192
  53. Borrello I, Sotomayor EM, Rattis FM, et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood. 2000;95:3011–3019
  54. Wrzesinski C, Paulos CM, Gattinoni L, et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. Journal of Clinical Investigation. 2007;117:492–501
  55. Badovinac VP, Messingham KA, Jabbari A, et al. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nature Medicine. 2005;11:748–756
  56. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854
  57. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology. 2005;23:2346–2357
  58. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. Journal of Experimental Medicine. 1982;155:1063–1074
  59. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. Journal of Immunology. 2005;174:2591–2601
  60. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. Journal of Experimental Medicine. 2004;200:771–782
  61. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nature Reviews. Immunology. 2003;3:269–279
  62. Surh CD, Sprent J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands?. Journal of Experimental Medicine. 2000;192:F9–F14
  63. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071–3079
  64. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480–1489
  65. Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. Journal of Clinical Immunology. 2000;20:195–202
  66. Sturrock AB, Franklin KF, Rao G, et al. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen. Journal of Biological Chemistry. 1992;267:21193–21199
  67. Dengler R, Munstermann U, al-Batran S, et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. British Journal of Haematology. 1995;89:250–257
  68. Bories D, Raynal MC, Solomon DH, et al. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell. 1989;59:959–968
  69. Franssen CF, Tervaert JW, Stegeman CA, et al. c-ANCA as a marker of Wegener's disease. Lancet. 1996;347:116
  70. Williams RC, Staud R, Malone CC, et al. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. Journal of Immunology. 1994;152:4722–4737
  71. Brouwer E, Stegeman CA, Huitema MG, et al. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clinical and Experimental Immunology. 1994;98:448–453
  72. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497
  73. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306:239–242
  74. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293
  75. Nieda M, Nicol A, Kikuchi A, et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood. 1998;91:977–983
  76. ten Bosch GJ, Kessler JH, Joosten AM, et al. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood. 1999;94:1038–1045
  77. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. Journal of Clinical Investigation. 1998;101:2290–2296
  78. Buzyn A, Ostankovitch M, Zerbib A, et al. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. European Journal of Immunology. 1997;27:2066–2072
  79. Greco G, Fruci D, Accapezzato D, et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia. 1996;10:693–699
  80. Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89:1133–1142
  81. Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. British Journal of Haematology. 2000;109:616–621
  82. Clark RE, Dodi IA, Hill SC, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 2001;98:2887–2893
  83. Malarkannan S, Horng T, Eden P, et al. Differences that matter: major cytotoxic T cell-stimulating minor histocompatibility antigens. Immunity. 2000;13:333–344
  84. Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. Journal of Antimicrobial Chemotherapy. 2000;45(Suppl. T3):35–43
  85. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549–1555
  86. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New England Journal of Medicine. 1995;333:1038–1044
  87. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129
  88. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24:363–373
  89. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:16168–16173
  90. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–712
  91. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. Journal of Clinical Investigation. 2008;118:294–305
  92. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 2005;106:3062–3067
  93. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nature Immunology. 2001;2:962–970
  94. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. Journal of Immunology. 1999;163:507–513
  95. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781–1787
  96. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103:1037–1042
  97. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657–662
  98. Rojas JM, Knight K, Wang L, et al. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007 Nov;21(11):2287–2295
  99. Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. ASH Annual Meeting Abstracts 2004; 104: 259.
  100. Qazilbash MH, Wieder E, Thall PF et al. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival. ASH Annual Meeting Abstracts 2007; 110: 577.
  101. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:13885–13890
  102. Morita S, Oka Y, Tsuboi A, et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Japanese Journal of Clinical Oncology. 2006;36:231–236
  103. Keilholz U, Letsch A, Aseminssen A, et al. Clinical and immune responses of WT1-peptide vaccination in patients with acute myeloid leukemia. 2006 Asco Annual Meeting Proceedings Part I. Journal of Clinical Oncology 2006; 24: 2511.
  104. Alpdogan O, Eng JM, Muriglan SJ, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood. 2005;105:865–873
  105. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:1969–1974
  106. Reddy V, Winer AG, Eksioglu E, et al. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2005;11:1014–1021
  107. Mielke S, Nunes R, Rezvani K, et al. A clinical scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood. 2007 Apr15;111(8):4392–4402
  108. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine. 2005;11:1230–1237
  109. Singh H, Serrano LM, Pfeiffer T, et al. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Research. 2007;67:2872–2880
  110. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236–242
  111. Ashton-Rickardt PG, Bandeira A, Delaney JR, et al. Evidence for a differential avidity model of T cell selection in the thymus. Cell. 1994;76:651–663
  112. Schild H, Rotzschke O, Kalbacher H, et al. Limit of T cell tolerance to self proteins by peptide presentation. Science. 1990;247:1587–1589
  113. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–458
  114. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Research. 1999;59:3128–3133
  115. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;108:1291–1297
  116. Mielke S, Rezvani K, Savani BN, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood. 2007;110:1689–1697
  117. Cozzo C, Larkin J, Caton AJ. Cutting edge: self-peptides drive the peripheral expansion of CD4+ CD25+ regulatory T cells. Journal of Immunology. 2003;171:5678–5682
  118. Hsieh CS, Liang Y, Tyznik AJ, et al. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity. 2004;21:267–277
  119. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4(+)CD25(+) regulatory T cells. Nature Medicine. 2005;11:1238–1243
  120. Litzinger MT, Fernando R, Curiel TJ, et al. The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007 Nov1;110(9):3192–3201
  121. Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+ CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. International Journal of Cancer. 2007;120:2723–2733
  122. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. Journal of Clinical Investigation. 2005;115:3623–3633

PII: S1521-6926(08)00060-1

doi: 10.1016/j.beha.2008.07.004

Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 437-453 , September 2008

Article Tools